CCL

Összesen 11 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM122762
035-os BibID:(Scopus)85198448771 (WoS)001266592600001
Első szerző:Borbásné Sebestyén Veronika (biofizikus)
Cím:Progranulin, sICAM-1, and sVCAM-1 May Predict an Increased Risk for Ventricular Arrhythmias in Patients with Systemic Sclerosis / Veronika Sebestyén, Balázs Ratku, Dóra Ujvárosy, Hajnalka Lőrincz, Dóra Tari, Lilla Végh, Gyöngyike Majai, Sándor Somodi, Dénes Páll, Gabriella Szűcs, Mariann Harangi, Zoltán Szabó
Dátum:2024
ISSN:1661-6596 1422-0067
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
systemic sclerosis
sudden cardiac death
electrocardiography
progranulin
CRP
Megjelenés:International Journal Of Molecular Sciences. - 25 : 13 (2024), p. 1-13. -
További szerzők:Ratku Balázs (1985-) (mentőtiszt) Ujvárosy Dóra (1985-) Lőrincz Hajnalka (1986-) (biológus) Tari Dóra (1992-) (orvos) Végh Lilla Majai Gyöngyike (1977-) (belgyógyász, immunológus) Somodi Sándor (1977-) (belgyógyász) Páll Dénes (1967-) (belgyógyász, kardiológus) Szűcs Gabriella (1963-) (belgyógyász, allergológus és klinikai immunológus, reumatológus) Harangi Mariann (1974-) (belgyógyász, endokrinológus) Szabó Zoltán (1973-) (belgyógyász, kardiológus)
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

2.

001-es BibID:BIBFORM126519
035-os BibID:(WoS)001393659000001 (Scopus)85214473384
Első szerző:Csengő Erika
Cím:Newly Initiated Statin Treatment Is Associated with Decreased Plasma Coenzyme Q10 Level After Acute ST-Elevation Myocardial Infarction / Csengo Erika, Lorincz Hajnalka, Csosz Eva, Guba Andrea, Karai Bettina, Toth Judit, Csiha Sara, Paragh Gyorgy, Harangi Mariann, Nagy Gergely Gyorgy
Dátum:2024
ISSN:1661-6596 1422-0067
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:International Journal Of Molecular Sciences. - 26 : 1 (2024), p. 1-18. -
További szerzők:Lőrincz Hajnalka (1986-) (biológus) Csősz Éva (1977-) (biokémikus, molekuláris biológus) Guba Andrea (1975-) (Okleveles vegyész) Kárai Bettina (1984-) (orvos) Tóth Judit (1978-) (laboratóriumi szakorvos) Csiha Sára (1985-) (Biológus) Paragh György (1953-) (belgyógyász) Harangi Mariann (1974-) (belgyógyász, endokrinológus) Nagy Gergely György (1976-) (orvos)
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

3.

001-es BibID:BIBFORM133189
Első szerző:Dániel Eszter (orvos)
Cím:Long-Term Effects of Semaglutide and Sitagliptin on Circulating IGFBP-1, IGFBP-3 and IGFBP-rp1 : results from a One-Year Study in Type 2 Diabetes / Dániel Eszter, Sztanek Ferenc, Csiha Sára, Ratku Balázs, Somodi Sándor, Paragh György, Harangi Mariann, Lőrincz Hajnalka
Dátum:2025
ISSN:1661-6596 1422-0067
Megjegyzések:The role of insulin-like growth factor-binding proteins (IGFBPs) in the regulation of carbohydrate metabolism and the development of complications is well established; however, the impact of the glucagon-like peptide-1 receptor agonist semaglutide on IGFBPs has not been previously investigated. We aimed to examine the effects of semaglutide and dipeptidyl peptidase-4 inhibitor sitagliptin therapy on serum levels of IGFBP-1, IGFBP-3, and IGFBP-rp1, and to analyze their associations with anthropometric variables and markers of carbohydrate and lipid metabolism. In this prospective study, we enrolled 34 patients with type 2 diabetes mellitus (T2DM) on metformin monotherapy and 31 age-, sex- and BMImatched controls. Among the patients, 18 received semaglutide, and 16 were treated with sitagliptin. Anthropometric and laboratory assessments were performed at baseline, 26 and 52 weeks. IGFBP levels were measured using ELISA. Both semaglutide and sitagliptin treatment significantly increased IGFBP-1 levels. IGFBP-3 levels were significantly decreased following sitagliptin therapy. No significant change in IGFBP-rp1 levels was observed with either treatment. Based on multiple regression analysis, the best predictors of IGFBP-1 were insulin and hsCRP, while the best predictor of IGFBP-3 was LDL-C level. Our findings suggest that semaglutide and sitagliptin may exert favorable effects on the GH/IGF-1 axis, potentially contributing to their beneficial metabolic outcomes in patients with T2DM.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
semaglutide
sitagliptin
insulin-like growth factor-binding protein
insulin
C-peptide
waist circumference
lipid parameters
C-reactive protein
type 2 diabetes mellitus
Megjelenés:International Journal Of Molecular Sciences. - 26 : 21 (2025), p. 1-14. -
További szerzők:Sztanek Ferenc (1982-) (orvos) Csiha Sára (1985-) (Biológus) Ratku Balázs (1985-) (mentőtiszt) Somodi Sándor (1977-) (belgyógyász) Paragh György (1953-) (belgyógyász) Harangi Mariann (1974-) (belgyógyász, endokrinológus) Lőrincz Hajnalka (1986-) (biológus)
Pályázati támogatás:K142273
OTKA
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

4.

001-es BibID:BIBFORM126140
035-os BibID:(Scopus)85213209914 (WoS)001384816200001
Első szerző:Hernyák Marcell (orvos)
Cím:Kallistatin as a Potential Marker of Therapeutic Response During Alpha-Lipoic Acid Treatment in Diabetic Patients with Sensorimotor Polyneuropathy / Hernyák Marcell, Tóth László Imre, Csiha Sára, Molnár Ágnes, Lőrincz Hajnalka, Paragh György, Harangi Mariann, Sztanek Ferenc
Dátum:2024
ISSN:1661-6596 1422-0067
Megjegyzések:Diabetic sensorimotor neuropathy (DSPN) is strongly associated with the extent of cellular oxidative stress and endothelial dysfunction in type 2 diabetes (T2DM). Alpha-lipoic acid (ALA) attenuates the progression of DSPN through its antioxidant and vasculoprotective effects. Kallistatin has antioxidant and anti-inflammatory properties. We aimed to evaluate changes in kallistatin levels and markers of endothelial dysfunction in patients with T2DM and DSPN following six months of treatment with 600 mg/day of ALA. A total of 54 patients with T2DM and DSPN and 24 control patients with T2DM but without neuropathy participated in this study. The serum concentrations of kallistatin, ICAM-1, VCAM-1, oxLDL, VEGF, ADMA, and TNF-alpha were measured by an ELISA. Peripheral sensory neuropathy was assessed with neuropathy symptom questionnaires and determination of the current perception threshold. After ALA treatment, the level of kallistatin significantly decreased, as well as the levels of TNF-alpha and ADMA. Changes in kallistatin levels were positively correlated with changes in oxLDL. The improvement in DSPN symptoms following ALA treatment showed a positive correlation with changes in kallistatin, VEGF, oxLDL, and ADMA levels. Based on our results, kallistatin could represent a potential new biomarker for assessing therapeutic response during ALA treatment in patients with DSPN.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
alpha-lipoic acid
diabetic sensorimotor neuropathy
endothelial dysfunction
kallistatin
type 2 diabetes
oxidative stress
Megjelenés:International Journal Of Molecular Sciences. - 25 : 24 (2024), p. 1-14. -
További szerzők:Tóth László (1997-) (orvos) Csiha Sára (1985-) (Biológus) Molnár Ágnes (1972-) (gyógytornász) Lőrincz Hajnalka (1986-) (biológus) Paragh György (1953-) (belgyógyász) Harangi Mariann (1974-) (belgyógyász, endokrinológus) Sztanek Ferenc (1982-) (orvos)
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

5.

001-es BibID:BIBFORM115431
035-os BibID:(WoS)001091853400001 (Scopus)85175252490
Első szerző:Juhász Lilla (általános orvos)
Cím:Decreased Serum Stromal Cell-Derived Factor-1 in Patients with Familial Hypercholesterolemia and Its Strong Correlation with Lipoprotein Subfractions / Lilla Juhász, Hajnalka Lőrincz, Anita Szentpéteri, Nóra Tóth, Éva Varga, György Paragh, Mariann Harangi
Dátum:2023
ISSN:1422-0067
Megjegyzések:Stromal cell-derived factor-1 (SDF-1) is a chemokine that exerts multifaceted roles in atherosclerosis. However, its association with hyperlipidemia is contradictory. To date, serum SDF-1 and its correlations with lipid fractions and subfractions in heterozygous familial hypercholesterolemia (HeFH) have not been investigated. Eighty-one untreated patients with HeFH and 32 healthy control subjects were enrolled in the study. Serum SDF-1, oxidized LDL (oxLDL) and myeloperoxidase (MPO) were determined by ELISA. Lipoprotein subfractions were detected by Lipoprint. We diagnosed FH using the Dutch Lipid Clinic Network criteria. Significantly lower serum SDF-1 was found in HeFH patients compared to healthy controls. Significant negative correlations were detected between serum total cholesterol, triglycerides, LDL-cholesterol (LDL-C), apolipoprotein B100 (ApoB100) and SDF-1. Furthermore, serum SDF-1 negatively correlated with VLDL and IDL, as well as large LDL and large and intermediate HDL subfractions, while there was a positive correlation between mean LDL-size, small HDL and SDF-1. SDF-1 negatively correlated with oxLDL and MPO. A backward stepwise multiple regression analysis showed that the best predictors of serum SDF-1 were VLDL and oxLDL. The strong correlation of SDF-1 with lipid fractions and subfractions highlights the potential common pathways of SDF-1 and lipoprotein metabolism, which supports the role of SDF-1 in atherogenesis.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
stromal cell-derived factor-1
familial hypercholesterolemia
oxidized low-density lipoprotein
very low-density lipoprotein
large low-density lipoprotein
vascular repair
Megjelenés:International Journal Of Molecular Sciences. - 24 : 20 (2023), p. 1-14. -
További szerzők:Lőrincz Hajnalka (1986-) (biológus) Szentpéteri Anita (1988-) (biológus) Tóth Nóra (1994-) (orvos) Varga Éva (1982-) (belgyógyász) Paragh György (1953-) (belgyógyász) Harangi Mariann (1974-) (belgyógyász, endokrinológus)
Pályázati támogatás:142273
OTKA
TKP2021-EGA-18
Egyéb
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

6.

001-es BibID:BIBFORM105181
035-os BibID:(WOS)000887302300001 (Scopus)85142806190
Első szerző:Juhász Lilla (általános orvos)
Cím:Sphingosine 1-Phosphate and Apolipoprotein M Levels and Their Correlations with Inflammatory Biomarkers in Patients with Untreated Familial Hypercholesterolemia / Juhász Lilla, Lőrincz Hajnalka, Szentpéteri Anita, Nádró Bíborka, Varga Éva, Paragh György, Harangi Mariann
Dátum:2022
ISSN:1422-0067
Megjegyzések:High-density lipoprotein (HDL)-bound apolipoprotein M/sphingosine 1-phosphate (ApoM/S1P) complex in cardiovascular diseases serves as a bridge between HDL and endothe lial cells, maintaining a healthy endothelial barrier. To date, S1P and ApoM in patients with untreated heterozygous familial hypercholesterolemia (HeFH) have not been extensively studied. Eighty-one untreated patients with HeFH and 32 healthy control subjects were included in this study. Serum S1P, ApoM, sCD40L, sICAM-1, sVCAM-1, oxLDL, and TNF? concentrations were determined by ELISA. PON1 activities were measured spectrophotometrically. Lipoprotein subfractions were detected by Lipoprint. We diagnosed FH using the Dutch Lipid Clinic Network criteria. Significantly higher serum S1P and ApoM levels were found in HeFH patients compared to controls. S1P negatively correlated with large HDL and positively with small HDL subfractions in HeFH patients and the whole study population. S1P showed significant positive correlations with sCD40L and MMP-9 levels and PON1 arylesterase activity, while we found significant negative correlation between sVCAM-1 and S1P in HeFH patients. A backward stepwise multiple regression analysis showed that the best predictors of serum S1P were large HDL subfraction and arylesterase activity. Higher S1P and ApoM levels and their correlations with HDL subfractions and inflammatory markers in HeFH patients implied their possible role in endothelial protection.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
sphingosine 1-phosphate
familial hypercholesterolemia
sCD40 ligand
apolipoprotein M
soluble vascular adhesion molecule-1
arylesterase activity
high-density lipoprotein
inflammation
Megjelenés:International Journal Of Molecular Sciences. - 23 (2022), p. 1-12. -
További szerzők:Lőrincz Hajnalka (1986-) (biológus) Szentpéteri Anita (1988-) (biológus) Nádró Bíborka (1992-) (általános orvos) Varga Éva (1982-) (belgyógyász) Paragh György (1953-) (belgyógyász) Harangi Mariann (1974-) (belgyógyász, endokrinológus)
Pályázati támogatás:OTKA-142273
OTKA
TKP2021-EGA-18
Egyéb
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

7.

001-es BibID:BIBFORM121807
035-os BibID:(Scopus)85195883546 (WoS)001245410600001
Első szerző:Lőrincz Hajnalka (biológus)
Cím:Associations between Serum Kallistatin Levels and Markers of Glucose Homeostasis, Inflammation, and Lipoprotein Metabolism in Patients with Type 2 Diabetes and Nondiabetic Obesity / Hajnalka Lőrincz, Sára Csiha, Balázs Ratku, Sándor Somodi, Ferenc Sztanek, György Paragh, Mariann Harangi
Dátum:2024
Megjegyzések:Kallistatin is an endogenous serine proteinase inhibitor with various functions, including antioxidative, anti-inflammatory, and anti-atherosclerotic properties. To date, associations between kallistatin and lipoprotein subfractions are poorly investigated. In this study, we enrolled 62 obese patients with type 2 diabetes (T2D), 106 nondiabetic obese (NDO) subjects matched in gender, age, and body mass index, as well as 49 gender- and age-matched healthy, normal-weight controls. Serum kallistatin levels were measured with ELISA, and lipoprotein subfractions were analyzed using Lipoprint? (Quantimetrix Corp., Redondo Beach, CA, USA) gel electrophoresis. Kallistatin concentrations were significantly higher in T2D patients compared to NDO and control groups. We found significant positive correlations between very-low-density lipoprotein (VLDL), small high-density lipoprotein (HDL) subfractions, glucose, hemoglobin A1c (HbA1c), betatrophin, and kallistatin, while negative correlations were detected between mean low-density lipoprotein (LDL) size, large and intermediate HDL subfractions, and kallistatin in the whole study population. The best predictor of kallistatin was HbA1c in T2D patients, high-sensitivity C-reactive protein (hsCRP) and betatrophin in NDO patients, and hsCRP in controls. Our results indicate that kallistatin expression might be induced by persistent hyperglycemia in T2D, while in nondiabetic subjects, its production might be associated with systemic inflammation. The correlation of kallistatin with lipid subfractions may suggest its putative role in atherogenesis.
Tárgyszavak:Orvostudományok Egészségtudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
kallistatin
triglyceride
lipid subfractions
diabetes
obesity
betatrophin
Megjelenés:International Journal of Molecular Sciences. - 25 : 11 (2024), p. 1-12. -
További szerzők:Csiha Sára (1985-) (Biológus) Ratku Balázs (1985-) (mentőtiszt) Somodi Sándor (1977-) (belgyógyász) Sztanek Ferenc (1982-) (orvos) Paragh György (1953-) (belgyógyász) Harangi Mariann (1974-) (belgyógyász, endokrinológus)
Pályázati támogatás:142273
OTKA
TKP2021-EGA-18
Egyéb
Eötvös Loránd Research Network (11003)
Egyéb
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

8.

001-es BibID:BIBFORM116322
035-os BibID:(WOS)001113721200001 (Scopus)85177740392
Első szerző:Lőrincz Hajnalka (biológus)
Cím:Gender-Dependent Associations between Serum Betatrophin Levels and Lipoprotein Subfractions in Diabetic and Nondiabetic Obese Patients / Hajnalka Lőrincz, Sára Csiha, Balázs Ratku, Sándor Somodi, Ferenc Sztanek, Ildikó Seres, György Paragh, Mariann Harangi
Dátum:2023
ISSN:1422-0067
Megjegyzések:Betatrophin, also known as angiopoietin-like protein 8 (ANGPTL8), mainly plays a role in lipid metabolism. To date, associations between betatrophin and lipoprotein subfractions are poorly investigated. For this study, 50 obese patients with type 2 diabetes (T2D) and 70 nondiabetic obese (NDO) subjects matched in gender, age, and body mass index (BMI) as well as 49 gender- and age-matched healthy, normal-weight controls were enrolled. Serum betatrophin levels were measured with ELISA, and lipoprotein subfractions were analyzed using Lipoprint gel electrophoresis. Betatrophin concentrations were found to be significantly higher in the T2D and NDO groups compared to the controls in all subjects and in females, but not in males. We found significant positive correlations between triglyceride, very low density lipoprotein (VLDL), large LDL (low density lipoprotein), small LDL, high density lipoprotein (HDL) -6-10 subfractions, and betatrophin, while negative correlations were detected between betatrophin and IDL, mean LDL size, and HDL-1-5. Proportion of small HDL was the best predictor of betatrophin in all subjects. Small LDL and large HDL subfractions were found to be the best predictors in females, while in males, VLDL was found to be the best predictor of betatrophin. Our results underline the significance of serum betatrophin measurement in the cardiovascular risk assessment of obese patients with and without T2D, but gender differences might be taken into consideration.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
betatrophin
angiopoietin-like protein 8
triglyceride
lipoprotein subfractions
high-density lipoprotein
diabetes
obesity
Megjelenés:International Journal Of Molecular Sciences. - 24 : 22 (2023), p. 1-13. -
További szerzők:Csiha Sára (1985-) (Biológus) Ratku Balázs (1985-) (mentőtiszt) Somodi Sándor (1977-) (belgyógyász) Sztanek Ferenc (1982-) (orvos) Seres Ildikó (1954-) (biokémikus) Paragh György (1953-) (belgyógyász) Harangi Mariann (1974-) (belgyógyász, endokrinológus)
Pályázati támogatás:K142273
OTKA
PD146136
OTKA
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

9.

001-es BibID:BIBFORM108875
035-os BibID:(Scopus)85149053802 (WoS)000945033100001
Első szerző:Lőrincz Hajnalka (biológus)
Cím:Impaired Organokine Regulation in Non-Diabetic Obese Subjects : halfway to the Cardiometabolic Danger Zone / Hajnalka Lőrincz, Balázs Ratku, Sára Csiha, Ildikó Seres, Zoltán Szabó, György Paragh, Mariann Harangi, Sándor Somodi
Dátum:2023
ISSN:1422-0067
Megjegyzések:Altered organokine expression contributes to increased cardiometabolic risk in obesity. Our aim was to evaluate the associations of serum afamin with glucose homeostasis, atherogenic dyslipidemia, and other adipokines in severe obesity to clarify the early metabolic alterations. 106 non diabetic obese (NDO) subjects and 62 obese patients with type 2 diabetes matched for age, gender, and body mass index (BMI) were enrolled in this study. We compared their data with 49 healthy, lean controls. Serum afamin and retinol-binding protein 4 (RBP4), as well as plasma plasminogen activator inhibitor-1 (PAI-1), were measured with ELISA, and lipoprotein subfractions were analyzed using Lipoprint gel electrophoresis. Afamin and PAI-1 found to be significantly higher in the NDO and T2M group (p < 0.001 and p < 0.001, respectively) than in the controls. In contrast, RBP4 was unexpectedly lower in the NDO and T2DM group compared to controls (p < 0.001). Afamin showed negative correlations with mean LDL size and RBP4, but positive correlations with anthropometric, glucose/lipid parameters, and PAI-1 in both the overall patients and the in NDO + T2DM groups. BMI, glucose, intermediate HDL, and small HDL were predictors of afamin. Afamin may serve as a biomarker for the severity of cardiometabolic disturbances in obesity. The complexity of organokine patterns in NDO subjects draws attention to the diverse spectrum of obesity-related comorbidities.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
obesity
type 2 diabetes
insulin resistance
afamin
plasminogen-activator inhibitor-1
retinol binding protein 4
lipid metabolism
lipoprotein subfraction
cardiometabolic
Megjelenés:International Journal Of Molecular Sciences. - 24 : 4 (2023), p. 1-13. -
További szerzők:Ratku Balázs (1985-) (mentőtiszt) Csiha Sára (1985-) (Biológus) Seres Ildikó (1954-) (biokémikus) Szabó Zoltán (1973-) (belgyógyász, kardiológus) Paragh György (1953-) (belgyógyász) Harangi Mariann (1974-) (belgyógyász, endokrinológus) Somodi Sándor (1977-) (belgyógyász)
Pályázati támogatás:PD124126
OTKA
K142273
OTKA
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

10.

001-es BibID:BIBFORM132951
035-os BibID:(scopus)105018892821 (wos)001594833500001
Első szerző:Rácz Lilla
Cím:Modulation of Paraoxonase 1 Activity and Asymmetric Dimethylarginine by Immunomodulatory Therapies in Multiple Sclerosis / Racz Lilla, Lorincz Hajnalka, Seres Ildiko, Kardos Laszlo, Paragh Gyorgy, Csepany Tunde
Dátum:2025
ISSN:1661-6596 1422-0067
Megjegyzések:Background: Neurodegeneration is present from the earliest stages of multiple sclerosis [MS], and oxidative stress together with mitochondrial dysfunction are key contributors to neuronal injury and disease progression. Objective: To investigate the role of the antioxidant enzyme paraoxonase 1 (PON1) and serum asymmetric dimethylarginine (ADMA) levels in MS across different disease subtypes and immunomodulatory treatments. Methods: Serum lipid levels and PON1 activity were measured and compared by disease subtype and treatment in a single-center MS cohort (N = 262; CIS = 10, RRMS = 208, PPMS = 19, SPMS = 25; 110 untreated, 152 treated) and in 91 healthy controls. ADMA levels were assessed in sera from 79 MS patients (19 untreated, 60 treated) and 31 age-matched controls. Results: Median serum paraoxonase (PON) and arylesterase (ARE) activity levels were 83.8 and 127.2 IU/L in MS patients versus 85.9 and 136.9 IU/L in controls, with no significant difference for PON (p = 0.191) but a significant reduction in ARE [p = 0.003]. PON activity differed significantly among disease subtypes (p = 0.023), with the highest levels in CIS. PON and ARE activity also varied across treatment groups (p = 0.038 and p = 0.034, respectively), with longitudinal analysis indicating a measurable effect of immunomodulatory therapy on PON activity at 10 years (p = 0.0136). Significant differences in enzyme activity were observed between untreated and interferon-treated patients (PON p = 0.0055, ARE p = 0.0001), with trends toward differences in ARE under natalizumab and fingolimod. ADMA levels were lower in MS patients than controls (p < 0.0001) and differed among treatment subgroups (natalizumab, dimethyl fumarate, glatiramer acetate, untreated RRMS). Conclusions: PON1 activity and ADMA levels differ between MS subgroups and under immunomodulatory treatments. Long-term therapy was associated with increased PON1 activity, while highly effective immunomodulators reduced ADMA levels. These changes may contribute to the treatment-related reduction in disease activity and attenuation of neurodegenerative processes in MS.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
multiple sclerosis
oxidative stress
paraoxonase 1
asymmetric dimethylarginine
immunomodulatory treatment
Megjelenés:International Journal Of Molecular Sciences. - 26 : 19 (2025), p. 1-14. -
További szerzők:Lőrincz Hajnalka (1986-) (biológus) Seres Ildikó (1954-) (biokémikus) Kardos László (1970-) (megelőző orvostan és népegészségtan szakorvos) Paragh György (1953-) (belgyógyász) Csépány Tünde (1956-) (neurológus, pszichiáter)
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

11.

001-es BibID:BIBFORM130785
035-os BibID:(WoS)001526345500001
Első szerző:Tóth László (orvos)
Cím:Semaglutide Improves Lipid Subfraction Profiles in Type 2 Diabetes : insights from a One-Year Follow-Up Study / Tóth László Imre, Harsányi Adrienn, Csiha Sára, Molnár Ágnes, Lőrincz Hajnalka, Nagy Attila Csaba, Paragh György, Harangi Mariann, Sztanek Ferenc
Dátum:2025
Megjegyzések:Recent studies have demonstrated the efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in enhancing glycemic control, regulating body weight, and modulating lipid metabolism. However, their effects on lipoprotein subfractions have not been clarified. The objective of this 52-week, single-center, randomized trial was to compare the effects of subcutaneous semaglutide administered once weekly and oral sitagliptin administered once daily on anthropometric measurements and lipoprotein subfractions measured by Lipoprint gelelectrophoresis in patients with type 2 diabetes mellitus (T2DM). A total of 34 obese individuals with T2DM were enrolled in the study and randomly assigned to receive semaglutide (n = 18) or sitagliptin (n = 16). Thirty-one age- and body weight-matched non-diabetic obese individuals served as controls. Semaglutide treatment resulted in significant reductions in body mass index (BMI), waist circumference, and HbA1c, along with improvements in lipid parameters, including reductions in LDL cholesterol and non-HDL cholesterol levels, and redistribution of LDL and HDL subfractions toward a less atherogenic profile. Conversely, sitagliptin elicited modest glycemic improvements without substantial alterations in lipid composition. Multivariate regression analysis demonstrated that fluctuations in lipoprotein subfractions were not influenced by changes in BMI or HbA1c. These results support the pleiotropic metabolic benefits of semaglutide and its potential role in managing the cardiometabolic risk of T2DM.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
type 2 diabetes mellitus
semaglutide
sitagliptin
lipoprotein subfractions
GLP-1 receptor agonist
cardiometabolic risk
Megjelenés:International Journal of Molecular Sciences. - 26 : 13 (2025), p. 1-18. -
További szerzők:Harsányi Adrienn Csiha Sára (1985-) (Biológus) Molnár Ágnes Lőrincz Hajnalka (1986-) (biológus) Nagy Attila Csaba (1981-) (megelőző orvostan és népegészségtan szakorvos, epidemiológus) Paragh György (1953-) (belgyógyász) Harangi Mariann (1974-) (belgyógyász, endokrinológus) Sztanek Ferenc (1982-) (orvos)
Pályázati támogatás:K142273
Egyéb
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Rekordok letöltése1 
Corvina könyvtári katalógus v10.11.18-SNAPSHOT © 2024 Monguz kft. Minden jog fenntartva.